Skip to main content
SpringerLink
Log in

Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials

  • Meta-Analyses
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The aim of this study was to assess the relative efficacy and tolerability of duloxetine, pregabalin, and milnacipran at the recommended doses in patients with fibromyalgia. Randomized controlled trials (RCTs) examining the efficacy and safety of duloxetine 60 mg, pregabalin 300 mg, pregabalin 150 mg, milnacipran 200 mg, and milnacipran 100 mg compared to placebo in patients with fibromyalgia were included in this Bayesian network meta-analysis. Nine RCTs including 5140 patients met the inclusion criteria. The proportion of patients with >30 % improvement from baseline in pain was significantly higher in the duloxetine 60 mg, pregabalin 300 mg, milnacipran 100 mg, and milnacipran 200 mg groups than in the placebo group [pairwise odds ratio (OR) 2.33, 95 % credible interval (CrI) 1.50–3.67; OR 1.68, 95 % CrI 1.25–2.28; OR 1.62, 95 % CrI 1.16–2.25; and OR 1.61; 95 % CrI 1.15–2.24, respectively]. Ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that duloxetine 60 mg had the highest probability of being the best treatment for achieving the response level (SUCRA = 0.9431), followed by pregabalin 300 mg (SUCRA = 0.6300), milnacipran 100 mg (SUCRA = 0.5680), milnacipran 200 mg (SUCRA = 0.5617), pregabalin 150 mg (SUCRA = 0.2392), and placebo (SUCRA = 0.0580). The risk of withdrawal due to adverse events was lower in the placebo group than in the pregabalin 300 mg, duloxetine 60 mg, milnacipran 100 mg, and milnacipran 200 mg groups. However, there was no significant difference in the efficacy and tolerability between the medications at the recommended doses. Duloxetine 60 mg, pregabalin 300 mg, milnacipran 100 mg, and milnacipran 200 mg were more efficacious than placebo. However, there was no significant difference in the efficacy and tolerability between the medications at the recommended doses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB (2010) The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 62:600–610

    Article  Google Scholar 

  2. Rossi A, Di Lollo A, Guzzo M, Giacomelli C, Atzeni F, Bazzichi L, Di Franco M (2015) Fibromyalgia and nutrition: what news. Clin Exp Rheumatol 33:S117–S125

    PubMed  Google Scholar 

  3. Clauw DJ (2015) Fibromyalgia and related conditions. Mayo Clin Proc 90:680–692

    Article  PubMed  Google Scholar 

  4. Theoharides TC, Tsilioni I, Arbetman L, Panagiotidou S, Stewart JM, Gleason RM, Russell IJ (2015) Fibromyalgia syndrome in need of effective treatments. J Pharmacol Exp Ther 355:255–263

    Article  CAS  PubMed  Google Scholar 

  5. Calandre EP, Rico-Villademoros F, Slim M (2015) An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother 16:1347–1368

    Article  CAS  PubMed  Google Scholar 

  6. Schuessler B (2006) What do we know about duloxetine’s mode of action? Evidence from animals to humans. BJOG Int J Obstet Gynaecol 113:5–9

    Article  CAS  Google Scholar 

  7. Leo RJ, Brooks VL (2006) Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs 7:637–642

    CAS  PubMed  Google Scholar 

  8. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ (2004) Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 55:320–322

    Article  CAS  PubMed  Google Scholar 

  9. Lyseng-Williamson KA, Siddiqui MA (2008) Pregabalin: a review of its use in fibromyalgia. Drugs 68:2205–2223

    Article  CAS  PubMed  Google Scholar 

  10. Häuser W, Petzke F, Sommer C (2010) Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 11:505–521

    Article  PubMed  Google Scholar 

  11. Lunn MP, Hughes RA, Wiffen PJ (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev (CDSR) 1:1–126

    Google Scholar 

  12. Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ (2015) Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev (CDSR) 10:1–70

    Google Scholar 

  13. Tzellos TG, Toulis KA, Goulis DG, Papazisis G, Zampeli VA, Vakfari A, Kouvelas D (2010) Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther 35:639–656

    Article  CAS  PubMed  Google Scholar 

  14. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG (2011) Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 38:3643–3651

    Article  CAS  PubMed  Google Scholar 

  15. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG (2007) PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int 27:827–833

    Article  CAS  PubMed  Google Scholar 

  16. Lee YH, Choi SJ, Ji JD, Song GG (2012) Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatol Int 32:417–426

    Article  CAS  PubMed  Google Scholar 

  17. Caldwell DM, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ Br Med J 331:897

    Article  Google Scholar 

  18. Lee YH, Bae SC, Song GG (2015) Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int 35:1965–1974

    Article  CAS  PubMed  Google Scholar 

  19. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum Arthritis Care Res 33:160–172

    Article  CAS  Google Scholar 

  20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12

    Article  CAS  PubMed  Google Scholar 

  21. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269

    Article  PubMed  Google Scholar 

  22. Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, Cameron C (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. Syst Rev 3:1–11

    Article  Google Scholar 

  23. Salanti G, Ades A, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171

    Article  PubMed  Google Scholar 

  24. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades A (2013) Evidence synthesis for decision making 4 inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33:641–656

    Article  PubMed  PubMed Central  Google Scholar 

  25. Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98–110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Valkenhoef G, Lu G, Brock B, Hillege H, Ades A, Welton NJ (2012) Automating network meta-analysis. Research synthesis. Methods 3:285–299

    Google Scholar 

  27. Arnold LM, Rosen A, Pritchett YL, D’Souza DN, Goldstein DJ, Iyengar S, Wernicke JF (2005) A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119:5–15

    Article  CAS  PubMed  Google Scholar 

  28. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136:432–444

    Article  CAS  PubMed  Google Scholar 

  29. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y (2008) Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 30:1988–2004

    Article  CAS  PubMed  Google Scholar 

  30. Branco JC, Zachrisson O, Perrot S, Mainguy Y, Multinational Coordinator Study G (2010) A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 37:851–859

    Article  CAS  PubMed  Google Scholar 

  31. Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y (2010) Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum Arthritis Care Res 62:2745–2756

    Article  CAS  Google Scholar 

  32. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LaMoreaux LK, Martin SA, Sharma U, Pregabalin -105 Study G (2005) Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum Arthritis Care Res 52:1264–1273

    Article  CAS  Google Scholar 

  33. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, Sharma U (2008) A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35:502–514

    CAS  PubMed  Google Scholar 

  34. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, Martin SA, Barrett JA, Haig G (2008) A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9:792–805

    Article  CAS  PubMed  Google Scholar 

  35. Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, Leon T, Zeiher B, Investigators A (2011) An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 38:2643–2652

    Article  CAS  PubMed  Google Scholar 

  36. Catalá-López F, Tobías A, Cameron C, Moher D, Hutton B (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int 34:1489–1496

    Article  PubMed  Google Scholar 

  37. Choy E, Smith C, Dore C, Scott D (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44:1414–1421

    Article  CAS  PubMed  Google Scholar 

  38. Ravindran V, Scott D, Choy E (2008) A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 67:855–859

    Article  CAS  PubMed  Google Scholar 

  39. Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P (2013) Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 72:955–962

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study is funded by a Korea University grant.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, Seoul, 02841, Korea

    Young Ho Lee & Gwan Gyu Song

Authors
  1. Young Ho Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gwan Gyu Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young Ho Lee.

Ethics declarations

Conflict of interest

Y. H. Lee and G. G. Song declare that they have no conflict of interests.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, Y.H., Song, G.G. Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int 36, 663–672 (2016). https://doi.org/10.1007/s00296-016-3468-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-016-3468-5

Keywords

Search

Navigation